Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Harmful BRCA1 and BRCA2 (breast cancer susceptibility genes 1 and 2) mutations greatly increase a woman’s lifetime risk of developing breast and ovarian cancers. Women with strong family histories of these cancers may attend genetic counselling, undergo genetic testing, and receive treatment if appropriate, but which women can access and ultimately choose to use these services may differ across cancer genetics communities.

This project examines ethical issues surrounding access to care for harmful BRCA1 and BRCA2 mutations, with particular emphasis on how patients’ experiences of cancer genetic services might be influenced by how genetics stakeholders (e.g. clinicians, patients, patient advocacy groups, policymakers, insurers, laboratory researchers, community leaders, etc.) interact in their community. Rigorous ethical analysis will be applied to theoretical research (literature review and analysis of UK and US professional guidelines, policy documents, and legal rulings) and empirical case study research on stakeholders in four geographically distinct cancer genetics communities (Oxford and Southampton in the UK, and Cambridge/Boston and Baltimore/Washington DC in the US).

Results will be developed into practical outputs such as patient and provider education materials, policy suggestions for how policymakers and clinicians might address specific barriers to care, and academic manuscripts on access to care.

Related research themes